News

PharmAla Secures Supply of LaNeo MDMA for Yale Study

PharmAla Secures Supply of LaNeo MDMA for Yale Study

PharmAla Supplies LaNeo MDMA for Clinical Research

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTC: MDXXF) announces an exciting advancement as it is contracted to provide LaNeo™ MDMA, a vital component for an ongoing clinical trial at Yale University. As a leader in the biotechnology sector, PharmAla prides itself on its dedication to the development and manufacturing of MDXX class molecules, particularly MDMA.

CEO's Insights on Clinical Trial Collaborations

In a recent statement, Nicholas Kadysh, the CEO of PharmAla, expressed the company’s enthusiasm about the growing interest in LaNeo™ MDMA for research purposes. He noted, “Requests for clinical trial material continue to occupy the Company at this time. We are happy to be well thought-of in academic circles and continue to collaborate with multiple research partners to deliver drug products for clinical trials promptly.” This collaboration not only underscores the importance of MDMA in therapeutic contexts but also suggests that PharmAla is firmly establishing itself as a reputable supplier in the academic research landscape.

Accessible Tools for Researchers

PharmAla offers researchers a dedicated tool which grants them access to crucial drug product quality data directly, enhancing the ease with which they can evaluate LaNeo MDMA for their studies. Thanks to their commitment to customer service, PharmAla ensures rapid support for converting clinical trial registrations and IRB approvals into comprehensive Chemistry, Manufacturing and Control packages for LaNeo MDMA.

Debt Settlement through Share Issuance

In addition to their supply agreement, PharmAla has recently announced a strategic move to address financial commitments. The board of directors has greenlit the settlement of $100,000 owed to arm’s length creditors through the issuance of common shares. The actual price per share will be determined at the time of settlement, showcasing the company’s proactive approach to managing its financial responsibilities while fostering its growth.

A Closer Look at PharmAla's Mission

Founded with a vision that merges the need for clinical-grade MDMA with the drive to innovate, PharmAla is committed to alleviating the global demand for generic, clinical-grade MDMA. This ambitious objective not only facilitates clinical trials but also positions PharmAla effectively for potential commercial sales across select regions.

Innovation in Research and Development

PharmAla has distinguished itself as the sole provider of clinical-grade MDMA for patient treatments outside clinical trials. Their dedicated research and development division has successfully completed proof-of-concept studies on various IP families, including its flagship drug candidate, ALA-002. With a regulatory-first approach, PharmAla operates under the ethos that forging excellent relationships with regulators is fundamental for success in the rapidly evolving psychedelics industry.

Contact Information for Queries

For any inquiries, interested parties can connect with Nicholas Kadysh, the Chief Executive Officer of PharmAla Biotech Holdings Inc. He can be reached by email at press@PharmAla.ca or via phone at 1-855-444-6362. More about the company can be found at www.PharmAla.ca.

Frequently Asked Questions

What is LaNeo MDMA?

LaNeo MDMA is a novel formulation of MDMA developed by PharmAla Biotech, specifically for research and clinical use.

Who is PharmAla Biotech Holdings Inc.?

PharmAla is a biotechnology company focusing on the development and manufacturing of MDXX class molecules like MDMA, with a commitment to clinical trials and therapeutic applications.

What are the aims of the clinical trial at Yale?

The clinical trial aims to study the effects and therapeutic potential of LaNeo MDMA in a controlled environment, aiding research into its applications in treatment.

How does PharmAla support researchers?

PharmAla provides tools and access to detailed drug product quality information and offers rapid support for clinical trial processes.

What recent financial steps has PharmAla taken?

The company is addressing its debts through the strategic issuance of shares, showing a proactive approach in managing financial commitments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Autohome Inc.'s Financial Results for 2025

Updated Category News Views 150

Autohome Inc.'s Upcoming Financial Results Announcement Autohome Inc. (NYSE: ATHM) is on the verge of announcing its financial results for the second quarter and six months period ending June 30, 2025. As a leading platform for automobile consumers, Autohome continues to grow and adapt in an evolving market. Key Details on the Earnings Announcement The earnings report...

Continue Reading
NEXGEL Welcomes Industry Expert Kip Crecca to Advisory Team

Updated Category News Views 100

NEXGEL Expands Scientific Expertise with New Appointment NEXGEL, Inc. (NASDAQ: NXGL), renowned for its innovative medical and over-the-counter (OTC) products, has recently announced an exciting development. The company is thrilled to welcome Kip Crecca to its Scientific Advisory Board. This strategic addition showcases NEXGEL's dedication to enhancing its healthcare...

Continue Reading
Exciting Mixed-Use Development Takes Shape in Downtown Area

Updated Category News Views 318

Reimagining Urban Spaces: The Lewter District Development In an exciting development for urban living, RNGD and Emergent Properties are pioneering a remarkable mixed-use community known as the Lewter District. This project is set on a 1.5-acre plot, featuring 14 townhomes, a Class A office building, and an inviting farm-to-table restaurant, bar, and bakery. It's an...

Continue Reading
37th Parallel Expands DFW Footprint with Key Acquisition

Updated Category News Views 97

Picking Up Momentum in Dallas-Fort Worth Real Estate 37th Parallel Properties isn't messing around in the Dallas-Fort Worth market. They've snapped up Woodbridge Villas, a prime multifamily asset with 222 units tucked away in Sachse, Texas—a place with more charm than lawn gnomes in spring. This acquisition helps them expand their already hefty footprint in the South...

Continue Reading
Microchip Technology Announces Revenue Changes and Restructuring

Updated Category News Views 169

Microchip Technology's Updated Revenue Guidance for December Quarter Recently, Microchip Technology Incorporated, a prominent provider of smart embedded control solutions, has updated its revenue outlook for the upcoming quarter. The latest forecasts indicate a decline, with expectations set close to the lower end of their original guidance at $1.025 billion. This...

Continue Reading